Can a protein predict chemo success in sarcoma?
NCT ID NCT04055753
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a protein called TOPO2A can help predict if the chemotherapy drugs doxorubicin or Doxil will shrink tumors in people with soft tissue sarcoma. About 24 patients whose next treatment plan includes one of these drugs will provide tumor tissue for testing. Researchers will track how well the tumor responds and how long patients live, to see if TOPO2A levels match up with treatment success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Doxorubicin or Doxil (chemotherapy drugs)
- What this could lead to
- If successful, this could help doctors choose which patients are most likely to benefit from these chemotherapy drugs, personalizing treatment.
- What could go wrong
- This is a very small, early-phase study (24 people) focused on a biomarker, not a treatment itself. The biomarker may not reliably predict response, and results may not apply to all sarcoma types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Drug duo takes on rare head and neck tumors